Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials

Area of Science:

• Immunology
• Vaccinology
• Biostatistics

Background:

• The enzyme-linked immunospot (ELISpot) assay is crucial for measuring cellular immune responses in HIV vaccine clinical trials.
• Accurate quantification of HIV-1-specific effector T lymphocyte responses is vital for understanding infection control.
• Current ELISpot assay readout often relies on dichotomous positive/negative criteria, which may be suboptimal with increased replicates.

Purpose of the Study:

• To propose and evaluate a novel, objective criterion for ELISpot assay data analysis.
• To control the false positive rate while preserving sensitivity for antigen-specific responses.
• To provide a more accurate summary of cellular immune responses in HIV research.

Main Methods:

• Development of a hypothesis-driven statistical method for ELISpot data analysis.
• Implementation of criteria to control the false positive rate.
• Comparison of the new approach with existing methods using real and simulated ELISpot data from HIV Vaccine Trials Network (HVTN) studies.

Main Results:

• The proposed objective criteria demonstrate effective control of false positive rates.
• The new method maintains sensitivity in detecting antigen-specific T lymphocyte responses.
• Performance evaluation indicates the new approach is a viable alternative to commonly used criteria.

Conclusions:

• A novel, objective criterion offers improved accuracy for ELISpot assay analysis in HIV research.
• This method enhances the reliability of measuring cellular immune responses in vaccine trials.
• The findings support the adoption of this approach for more precise HIV immunology studies.